Chlamydia trachomatis (CT) is a Gram-negative, obligate intracellular parasite that can infect mucosal epithelial cells such as the urethra, vagina, and nasopharynx, as well as the conjunctiva, causing diseases such as trachoma, urethritis, cervicitis, and neonatal conjunctivitis. Among them, L2 CT can cause sexually transmitted lymphogranuloma, which is more invasive than other serotypes and requires long-term treatment, receiving widespread attention. Research has shown that the production of erythropoietin producing hepatocyte receptor A2 (EphA2) on the cell surface can mediate the adhesion and invasion of CT L2, and interfering with their interaction can significantly reduce the infection of CT L2. This study conducted bioinformatics analysis on human cervical epithelial cells infected with CT L2 and found that EphA2 expression was significantly upregulated in the infected group. This study successfully constructed, expressed, and purified a bivalent antibody targeting EphA2, named as EphA2-scFv-Fc. Through ELISA experiments, it was confirmed that there is a dose-dependent specific binding between EphA2-scFv-Fc and EphA2 receptors on the surface of CT L2 susceptible cells HUVEC. This study not only revealed the crucial role of EphA2 in the process of CT infection, but also successfully developed bivalent antibodies that can specifically target EphA2, providing an important foundation for the treatment of CT L2 infection.
Key words
Chlamydia trachomatis /
Erythropoietin Producing Hepatocyte Receptor A2 /
Bivalent Antibody
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1]TAYLOR H R, BURTON M J, HADDAD D, et al.Trachoma[J].The Lancet, 2014, 384(9960):2142-52
[2]NEWMAN L, ROWLEY J, VANDER HOORN S, et al.Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting[J].PLOS ONE, 2015, 10(12):e0143304-e0143304
[3]STARK D, VAN HAL S, HILLMAN R, et al.Lymphogranuloma venereum in Australia: anorectal Chlamydia trachomatis serovar L2b in men who have sex with men[J].Journal of clinical microbiology, 2007, 45(3):1029-31
[4]DESSUS-BABUS S, MOORE C G, WHITTIMORE J D, et al.Comparison of Chlamydia trachomatis serovar L2 growth in polarized genital epithelial cells grown in three-dimensional culture with non-polarized cells[J].Microbes and Infection, 2008, 10(5):563-70
[5]KAPOOR S.Re-emergence of lymphogranuloma venereum[J].Journal of the European Academy of Dermatology and Venereology, 2008, 22(4):409-16
[6]NIEUWENHUIS R F, OSSEWAARDE J M, G?TZ H M, et al.Resurgence of lymphogranuloma venereum in Western Europe: an outbreak of Chlamydia trachomatis serovar l2 proctitis in The Netherlands among men who have sex with men[J].Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, 39(7):996-1003
[7]ELWELL C, MIRRASHIDI K, ENGEL J.Chlamydia cell biology and pathogenesis[J].Nature reviews Microbiology, 2016, 14(6):385-400
[8]KOTTOM T J, CARMONA E M, LIMPER A H.Targeting host tyrosine kinase receptor EphA2 signaling via small-molecule ALW-II-41-27 inhibits macrophage pro-inflammatory signaling responses to Pneumocystis carinii β-glucans[J].Antimicrobial agents and chemotherapy, 2024, 68(2):e0081123-e0081123
[9]PASQUALE E B.Eph receptors and ephrins in cancer: bidirectional signalling and beyond[J].Nature Reviews Cancer, 2010, 10(3):165-80
[10]SUBBARAYAL P, KARUNAKARAN K, WINKLER A-C, et al.EphrinA2 Receptor (EphA2) Is an Invasion and Intracellular Signaling Receptor for Chlamydia trachomatis[J].PLOS Pathogens, 2015, 11(4):e1004846-e1004846
[11]WEINREICH DAVID M, SIVAPALASINGAM S, NORTON T, et al.REGN-COV2,a Neutralizing Antibody Cocktail,in Outpatients with Covid-19[J].New England Journal of Medicine, 2021, 384(3):238-51
[12]WHALEY K J, ZEITLIN L.Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing[J].Human vaccines & immunotherapeutics, 2022, 18(2):1930847-1930847
[13]MOTLEY M P, BANERJEE K, FRIES B C.Monoclonal antibody-based therapies for bacterial infections[J].Current opinion in infectious diseases, 2019, 32(3):210-6
[14]REZAIE E, AMANI J, BIDMESHKI POUR A, et al.A new scfv-based recombinant immunotoxin against EPHA2-overexpressing breast cancer cells; High in vitro anti-cancer potency.[J].European Journal of Pharmacology, 2020, 870(/):172912-172912
[15]HOUDEBINE L-M.Antibody manufacture in transgenic animals and comparisons with other systems[J].Current Opinion in Biotechnology, 2002, 13(6):625-9
[16]PINI A, BRACCI L.Phage display of antibody fragments[J].Current Protein and Peptide Science, 2000, 1(2):155-69
[17]CZAJKOWSKY D M, HU J, SHAO Z, et al.Fc-fusion proteins: new developments and future perspectives[J].EMBO molecular medicine, 2012, 4(10):1015-28
[18]HOLLIGER P, HUDSON P J.Engineered antibody fragments and the rise of single domains[J].Nature Biotechnology, 2005, 23(9):1126-36
